October 16, 2023 News by Marisa Wexler, MS ECTRIMS 2023: More disease activity when treatment stopped A clinical trial that was testing if treatments for multiple sclerosis (MS) could be discontinued in people with stable disease was terminated early after several patients who stopped treatment saw new disease activity. The findings support the continued…
October 13, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Personalized dosing of Tysabri shows good efficacy A personalized dosing schedule for Tysabri (natalizumab) that aims to maintain blood levels of the drug above a certain threshold seems to be just as effective for controlling disease activity in relapsing-remitting multiple sclerosis (RRMS) as the…
October 13, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Early high-efficacy DMTs may help slow MS disability People with relapsing-remitting multiple sclerosis (RRMS) who had an early start on high-efficacy disease-modifying therapies (DMTs) experience slower disability progression compared with those on escalation treatment, according to recent research. The study, which followed patients for up…
October 13, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Treating SPMS with OCH shows promise in small study Five of six people with secondary progressive multiple sclerosis (SPMS) treated with an experimental oral therapy called OCH saw no disease activity over six months in a small clinical trial. That’s compared with 0% of the SPMS patients…
October 12, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Under-the-skin Ocrevus found to be powerful in MS A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as the approved intravenous, or into-the-vein, formulation among people with multiple sclerosis (MS), according to new clinical trial data.
October 12, 2023 News by Marisa Wexler, MS ECTRIMS 2023: EBV may trigger attack on brain protein ANO2 Infection with the Epstein-Barr virus (EBV) may prime the immune system to accidentally attack a brain protein called ANO2, new research shows. The findings may explain how EBV infection can lead to developing multiple sclerosis (MS), at…
October 11, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Vidofludimus calcium lowers RRMS nerve damage Six months of treatment with the experimental oral therapy vidofludimus calcium (IMU-838) led to significant reductions in a marker of nerve damage among people with relapsing-remitting multiple sclerosis (RRMS), according to a new analysis of data from a…